Please use this identifier to cite or link to this item:
Title: Outcomes of off-label drug uses in hospitals: a multicentric prospective study
Author: Danés, I.
Agustí, A.
Vallano Ferraz, Antonio
Alerany, C.
Martínez, J.
Bosch, J. A.
Ferrer, A.
Gratacós, L.
Pérez, A.
Olmo, M.
Cano Marron, S. M.
Valderrama, A.
Bonafont, X.
Keywords: Medicina clínica
Assaigs clínics de medicaments
Malalts hospitalitzats
Clinical medicine
Drug testing
Hospital patients
Issue Date: 9-Sep-2014
Publisher: Springer Verlag
Abstract: Purpose: The study aims to assess the clinical evidence, outcome and cost of off-label use of medicines in the hospital setting. Methods: A multicentric prospective cohort study of patients treated with off-label medicines was carried out in five tertiary hospitals from May 2011 to May 2012. Information on clinical characteristics of patients, drugs, outcomes and costs was collected. Patients were followed up to 6 months, and information was assessed by reviewing clinical records and interviewing physicians. Results: A total of 226 patients were included. The median (interquartile range (IQR)) age of patients was 46 (33<br>62) years; 59 % were women. Patients had received a median of three previous treatments, and a lack of response (or suboptimal) was the main reason for off-label use (72.1 %). A total of 232 off-label medicines were administered for 102 different indications. The most frequent medicines were rituximab (49; 21.1 %), botulinum toxin (25; 10.7 %) and omalizumab (14; 6.0 %). In 117 (51.8 %) cases, the level of clinical evidence for their use was low. A partial clinical response was observed in 82 patients (36.3 %), complete response in 71 (31.4 %) and stabilization in 11 (4.9 %). A total of 58 (26.5 %) patients had adverse effects, which in 11 (4.9 %) were severe. The median (IQR) cost per patient was 2,943.07 (541.9<br>5,872.54). Conclusions: There was a high variability of off-label medicines and indications. Although the clinical evidence of off-label medicines was often low, clinical response was observed in many patients with previous multiple treatment failure, but at the expense of some adverse effects and a high cost. Registers of patients would be helpful for clinical decisions, although clinical trials are needed.
Note: Versió postprint del document publicat a:
It is part of: European Journal of Clinical Pharmacology, 2014, vol. 70, num. 11, p. 1385-1393
Related resource:
ISSN: 0031-6970
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
648239.pdf127.58 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.